Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Essen – page 30

989 clinical trials in Essen, Germany across 8 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Essen at a glance
989
clinical trials
  • Research sites8
Type of trial
Recruitment status
Quick filters

989 trials in Essen

Open in trial search

Glioblastoma

Recruiting

Study on Glioblastoma Recurrence: Comparing SonoCloud-9 with Carboplatin to Standard Treatments Lomustine or Temozolomide for Patients Undergoing Tumor Removal Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Carthera

Hormone-dependent prostate cancer+1

Recruiting

Study on Lutetium (177Lu) Vipivotide Tetraxetan to Delay Recurrence in Adult Men with PSMA-Positive Oligometastatic Prostate Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Novartis Pharma AG

Mantle cell lymphoma stage II+2

Recruiting

Study on CAR-T-cell Therapy with Rituximab and Ibrutinib for Patients with High-Risk Mantle Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Klinikum Der Universitat Munchen AöR

Prostate cancer

Recruiting

Study of Lutetium (177Lu) Vipivotide Tetraxetan for Patients with High-Risk Localized or Locally Advanced Prostate Cancer Eligible for Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177Lu) Vipivotide Tetraxetan
  • Sponsor:Universitaetsklinikum Essen AöR

Study on Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan for Adults with Prostate Cancer

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177Lu) Vipivotide Tetraxetan
  • Sponsor:Novartis Pharma AG

Duchenne muscular dystrophy

Recruiting

Efficacy and Safety of Givinostat for Non-Ambulant Patients with Duchenne Muscular Dystrophy

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Givinostat
  • Sponsor:Italfarmaco S.p.A.

Nasopharyngeal cancer

Recruiting

Study of Nivolumab, Cisplatin, and 5-Fluorouracil for Children and Adults with EBV-Positive Nasopharyngeal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:GPOH gGmbH

Hormone receptor positive breast cancer+2

Recruiting

Study on Ribociclib and Drug Combination for Patients with Advanced HER2-Negative, Hormone Receptor Positive Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Institut fuer Frauengesundheit GmbH

Renal transplant

Recruiting

Study on Switching from Tacrolimus or Ciclosporin to Belatacept for Adolescents with Kidney Transplants

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Belatacept
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Anaplastic large cell lymphoma T- and null-cell types

Recruiting

Study on Vinblastine for Children and Adolescents with Standard Risk ALK-Positive Anaplastic Large Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Vinblastine Sulfate
  • Sponsor:GPOH gGmbH

Allogenic stem cell transplantation

Recruiting

Study on MaaT033 to Prevent Complications in Patients with Blood Cancer Undergoing Stem Cell Transplantation

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Faecal Microbiota, Pooled
  • Sponsor:Maat Pharma

Metastatic malignant melanoma

Recruiting

Study Comparing Subcutaneous and Intravenous Nivolumab and Relatlimab for Patients with Untreated Metastatic or Unresectable Melanoma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Essen

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on metastatic colorectal cancer, breast cancer, and lymphoma treatments. Studies evaluate novel therapeutic combinations and targeted approaches for various cancer types.

  • HER2-positive breast cancer therapies
  • Diffuse Large B-Cell Lymphoma treatments
  • Metastatic prostate cancer interventions

Research includes evaluation of new drug combinations and immunotherapy approaches.

02 Respiratory Medicine

Studies examining preventive treatments for respiratory syncytial virus and related infections. Research focuses on vaccine development and immune response in different age groups.

  • RSV vaccine efficacy studies
  • Human Metapneumovirus research
  • Pneumococcal disease prevention

Emphasis on protecting vulnerable populations including older adults and at-risk individuals.

03 Neurological Disorders

Clinical research addressing Alzheimer's disease and acute cerebral ischemic stroke. Investigations into novel therapeutic approaches and diagnostic tools.

  • Early-stage Alzheimer's treatment
  • Stroke recovery interventions
  • Spinal muscular atrophy therapies

Focus on improving patient outcomes through innovative treatment strategies.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.